Market Signal Briefing

October 17, 2025 07:30 ET

 | Source:

SL Green Realty Corp

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2575 per share of common stock, which is the equivalent of an annualized dividend of $3.09 per share. The dividend is payable in cash on November 17, 2025 to shareholders of record at the close of business on October 31, 2025.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan's largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of September 30, 2025, SL Green held interests in 53 buildings totaling 30.7 million square feet. This included ownership interests in 27.1 million square feet of Manhattan buildings and 2.7 million square feet securing debt and preferred equity investments.

Forward Looking Statement

This press release includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, including such matters as future capital expenditures, dividends and acquisitions (including the amount and nature thereof), development trends of the real estate industry and the New York metropolitan area markets, occupancy, business strategies, expansion and growth of our operations and other similar matters, are forward-looking statements. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend," "project," "continue," or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

PRESS CONTACT
[email protected]

SLG – DIV

Victoria, British Columbia, Canada, October 17, 2025.  Teuton Resources Corp.  (“Teuton” or “the Company”) (“TUO”-TSX-V) ("TFE"- Frankfurt) is pleased to report that Joint Venture (“JV”) partner Tudor Gold ("Tudor") has announced, in a news release dated October 16, 2025, encouraging results from the fourth hole of the 2025 exploration drill program at the Treaty Creek Project, located in the Golden Triangle of Northwest British Columbia.  Teuton owns a 20% carried interest (carried until a production decision is made) in the Treaty Creek JV as well as a 0.98% Net Smelter Royalty in the core portion of the Treaty Creek property (includes the Goldstorm Deposit) with no buyback.

Drilling Highlights:

Hole GS-25-191 intersected a southwestward extension of the 300 North Zone (“300N”), linking mineralized intercepts within the 300N and 300 Horizon Zone (“300H”) along a potential SC-1 Zone structural corridor, now extending approximately 350 m by 150 m. Highlights of the mineralized intercept:

1.70 g/t gold, 12.56 g/t silver and 0.02% copper (1.85 g/t gold equivalent (“AuEQ”)) over 46.00 m, including:

4.12 g/t gold, 16.48 g/t silver and 0.01% copper (4.30 g/t AuEQ) over 8.90 m, and:

1.91 g/t gold, 25.06 g/t silver and 0.01% copper (2.17 g/t AuEQ) over 7.40 m

See Table 1 below for select drill results of hole GS-25-191 accompanied by a plan map and cross section.

GS-25-191 was targeted to infill high-grade mineralization between 300N and 300H and provide continuity between the two previously unconnected zones. This drill hole expands the mineralized footprint of 300N by 55 m to the southwest and 300H by 110 m to the northeast. In addition, the intercepted mineralization occurs along a structural orientation similar to the previously identified four sub-parallel gold-bearing breccia systems of the SC-1 Zone. Mineralization along this axis provides additional pierce points connecting 300H and 300N Zones.

Drilling continues to confirm the higher-grade gold structures within the bulk-tonnage Mineral Resource at Treaty Creek. The upcoming Mineral Resource estimate for Treaty Creek will, in addition to updating the overall Mineral Resource, also provide sensitivity analysis of the tonnes and grade above 2 g/t gold. This analysis will provide Tudor with the ability to assess the potential for a higher-grade underground mine with a smaller footprint to kickstart gold production.

Remaining Drill Hole

The results from the remaining drill hole from the 2025 Exploration Program will be released in the coming weeks.

Table 1: Select Drill Results for Drillhole GS-25-191

Hole

Collar Coords

Dip/

Azimuth

From

(m)

To

(m)

Interval

(m)

Gold

(g/t)

Silver

(g/t)

Copper

(%)

AuEQ(3)

(g/t)

GS-25-191

428884 mE

6273677 mN

-64/245

776.50

822.50

46.00

1.70

12.56

0.02

1.85

 
 

including

782.00

790.90

8.90

4.12

16.48

0.01

4.30

 
 

and

812.10

819.50

7.40

1.91

25.06

0.01

2.17

 

·       All assay values are uncut and intervals reflect drilled intercept lengths.

·       HQ and NQ diameter core samples were sawn in half and typically sampled at standard 1.5 m intervals.

·       The following metal prices were used to calculate the Au Eq metal content: Gold $1850/oz, Ag: $21/oz, Cu: $3.75/lb. Calculations used the formula AuEQ = Au g/t + (Ag g/t*0.0100901) + (Cu ppm*0.0001236). All metals are reported in USD and calculations consider recoveries of 90 % for gold, 80 % for copper, and 80 % for silver.

·        True widths have not been determined as the mineralized body remains open in all directions. Further drilling is required to determine the mineralized body orientation and true widths.

Plan Map of Drillhole GS-25-191

Click Image To View Full Size

Cross Section of Drillhole GS-25-191

Click Image To View Full Size

Qualified Person

The Qualified Person for the Tudor Gold news release dated Oct. 16, 2025 for the purposes of National Instrument 43-101 is Ken Konkin, P. Geo., Senior Vice President, Exploration, Tudor Gold.  Ken Konkin has read and approved the scientific and technical information that forms the basis for the disclosure contained in this news release.  D. Cremonese, P. Eng. Is the Qualified Person for Teuton Resources.  Technical data presented in today’s Teuton news release is consistent with that presented in the Tudor Gold news release of October 16, 2025. As Mr. Cremonese is President and also director of Teuton, he is not independent of the Company.

QA/QC

Diamond drill core samples were prepared at MSA Labs’ Preparation Laboratory in Terrace, BC and assayed at MSA Labs’ Geochemical Laboratory in Langley, BC. Analytical accuracy and precision are monitored by the submission of blanks, certified standards and duplicate samples inserted at regular intervals into the sample stream by Tudor Gold personnel. MSA Laboratories quality system complies with the requirements for the International Standards ISO 17025 and ISO 9001. MSA Labs is independent of the Company.

About Treaty Creek

Teuton was the original staker of the Treaty Creek property, host to the large Goldstorm deposit, assembling the core land position in 1984-5.  It presently holds a 20% carried interest in the Treaty Creek Project (Tudor Gold is responsible for paying all exploration costs up until such time as a production decision is made and owns an 80% interest).  Additionally, Teuton owns a 0.98% Net Smelter Royalty in the Goldstorm deposit area as well as in the northern portion of the Perfectstorm zone; within the southern portion of the Perfectstorm zone, Teuton owns a 0.49% NSR with an option to increase that to 1.49% by paying $1 million to the current owner.  It also owns numerous additional royalty interests within the Sulphurets Hydrothermal system on formerly 100%-owned properties such as the King Tut, Tuck, High North, Orion, Delta and Fairweather properties (King Tut and Tuck now owned by Newmont Mining; High North, Orion, Delta and Fairweather properties now owned by Goldstorm Metals).

The Treaty Creek Project not only contains the Goldstorm Deposit (a large gold-copper porphyry system) it also hosts several other prospective zones of mineralization lying along a north-northeast trending axis following the trace of the Sulphurets thrust fault.   This thrust fault is spatially related to all of the porphyry deposits on the neighbouring KSM property (owned by Seabridge Gold) as well as the Treaty Creek property.  

About Teuton

Teuton owns interests in more than twenty-three properties in the prolific “Golden Triangle” area of northwest British Columbia and was one of the first companies to adopt what has since become known as the “prospect generator” model.  This model minimizes share equity dilution while at the same time maximizing opportunity.  Earnings provided from option payments received, both in cash and in shares of the optionee companies over the past 9 years, has provided Teuton with substantial income.

ON BEHALF OF THE BOARD OF DIRECTORS OF TEUTON RESOURCES:

"Dino Cremonese"

Dino Cremonese, P. Eng.,

President and Chief Executive Officer

For further information, please visit the Company's website at www.teuton.com or contact:

Barry Holmes

Director Corporate Development and Communications

Tel. 778-430-5680

Email:  [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements regarding Forward-Looking information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially.

All statements relating  to future plans, objectives or expectations of the Company are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's plans or expectations include risks relating to the actual results of current exploration activities, fluctuating gold prices, possibility of equipment breakdowns and delays, exploration cost overruns, availability of capital and financing, general economic, market or business conditions, regulatory changes, timeliness of government or regulatory approvals and other risks detailed herein and from time to time in the filings made by the Company with securities regulators. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise except as otherwise required by applicable securities legislation.

The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise except as otherwise required by applicable securities legislation.

  

October 17, 2025 07:30 ET

 | Source:

Prelude Therapeutics, Incorporated

WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking.

“Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team,” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We welcome her to our board and we look forward to her immediate contributions as we aim to advance our precision oncology drug candidates.”

Ms. Dorton was most recently Chief Financial Officer at NodThera. Prior to NodThera, she most recently built and led the finance organization for Repare Therapeutics, where she prepared the company for an IPO and raised more than $82 million in crossover funding. Ms. Dorton also served in senior finance roles at AVROBIO, Inc. and Immatics N.V. Prior to joining industry, Ms. Dorton spent 15 years as an investment banker with Morgan Stanley and Neeham & Co. Ms. Dorton currently serves on the board of directors at Mallinckrodt Pharmaceuticals plc, Fulcrum Therapeutics, TScan Therapeutics and Sonoma Biotherapeutics. Ms. Dorton received a B.A. from Duke University an M.B.A from George Washington University and a J.D. from University of Virgina School of Law.

“Prelude has an exciting pipeline of novel precision oncology drug candidates, a strong, experienced leadership team and the opportunity to create significant shareholder value,” stated Ms. Dorton. “I am excited for the opportunity to work closely with this team along with my fellow board members to help guide the company towards meeting its strategic goals.”

Ms. Dorton will succeed Mardi C. Dier, who will be resigning from the Prelude board effective October 17, 2025. Ms. Dorton will also succeed Ms. Dier as Audit Committee Chair at that time. Ms. Dier has served on Prelude’s board since August 2020.

“I want to take this moment to thank Mardi for her devoted service and invaluable contributions during her time on Prelude’s board,” continued Vaddi. “She has been an important resource to me professionally and others on our executive leadership team since becoming a public company in 2020. On behalf of the entire company, we wish Mardi continued success in her endeavors.”

About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders, and ongoing research into other precision oncology targets. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at Events & Presentations - Prelude Therapeutics. For more information, visit preludetx.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway into the second quarter of 2026. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.

Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated
484.639.7235
[email protected]

HOUSTON, TEXAS / ACCESS Newswire / October 17, 2025 / XCF Global, Inc. ("XCF") (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Sustainable Aviation Fuel ("SAF"), today announces that it has filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025, with the U.S. Securities and Exchange Commission ("SEC"). As a result of the filing, the company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC.

VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- ExGen Resources Inc. (TSX.V: EXG; OTC: BXXRF) (“ExGen”, the “Company”) and MTB Metals Corp. (TSXV: MTB, OTCQB: MBYMF, Frankfurt: M9U) (“MTB”): ExGen and MTB are pleased to announce that they have entered into an Arrangement Agreement dated October 16, 2025 (the “Arrangement”). The Arrangement sets terms and conditions between ExGen and MTB pursuant to which ExGen and MTB will combine their operations, business, assets and properties (the “Proposed Transaction”). The Proposed Transaction will be subject to approval by MTB shareholders, the court, and the TSX Venture Exchange (the “TSX-V”), and other closing conditions customary in transactions of this nature. The Proposed Transaction will be an Arm’s Length Transaction for both companies under the policies of the TSX-V. There are no finders fees.

TERMS OF THE PROPOSED TRANSACTION

Under the Proposed Transaction, ExGen would acquire all the issued and outstanding securities of MTB, on the basis of 0.286 of an ExGen share for each MTB share, with the result that the current securityholders of MTB will become securityholders of ExGen and will hold approximately 35% of the combined company (subject to potential changes resulting from other potential transactions).

Signing of the Arrangement Agreement advances the proposed transaction from the Letter of Intent that was announced on August 13, 2025. In addition to setting definitive terms and conditions, both companies have now initiated work on National Instrument 43-101 (“NI 43-101”) reports on their flagship projects.

BENEFITS OF THE PROPOSED TRANSACTION

The Proposed Transaction would create a well funded exploration and development company with a strong balance sheet, a stronger combined management and technical team and assets in multiple favorable jurisdictions.Consolidation of the DOK property interest with the balance of MTB’s Telegraph copper-gold project in the fertile Golden Triangle of British Columbia.Exposure for MTB’s shareholders to ExGen’s 20% carried interest in the Empire copper-gold development-stage mine in Idaho as well as to ExGen’s other copper and lithium projects.
Lawrence Roulston, CEO of MTB, commented, “This merger combines MTB's exposure to copper and gold projects with ExGen’s carried interest in the development-stage Empire copper mine. The Empire interest offers a clear path to near-term cash flow. The combined company will have a strong balance sheet, providing a solid basis for an evolving business plan in which exploration expenditures will be funded by others. We intend to continue to expand our portfolio of royalties and carried interests as well as continuing a highly selective exploration program aimed at acquiring high potential prospects with potential to quickly unlock value."

Jason Riley, CEO of ExGen, commented, “Over the past few years, ExGen has actively sought the right transactions to expand our portfolio as we believed the metal and resource markets were due for a rebound. Now, together with MTB, our combined companies’ will be ideally positioned with the right assets, the right technical and management team, and a rising metals market. The Proposed Transaction provides our shareholders with incredible leverage to both near-term production potential and a new porphyry discovery, and in a time of rising copper and gold prices. We look forward to providing further updates on a number of potential catalysts across our portfolio throughout the rest of this year.”

ASSETS OF EXGEN

Empire Mine: ExGen holds an effective 20% carried interest in the Empire Mine project in Idaho. A 2020 NI 43-101 Resource Calculation outlined an open pit mine plan(1). Sulphide veins underlying the open pit area were historically mined from underground. A 2021 drillhole encountered 8.4% copper along with significant values of gold, silver, and zinc over 0.5m, for further information see ExGen news release dated December 10, 2021. The sulphide vein zone represents considerable upside potential for the project.

Dok Project, BC: ExGen holds the Dok claims, representing 27% of the area of MTB’s Telegraph project in British Columbia’s Golden Triangle.

Spark North Lithium Project, Nevada: 2300 acres of unpatented claims in Elko County, Nevada, directly north of Surge Battery Metals Inc’s Nevada North Lithium Project.

Buena Vista Copper Project, Nevada: a copper and gold project with field work in 2011 and 2012 identifying extensive areas of copper mineralization and two large areas of chargeability (2).

Gordon Lake Project, NWT: A high-grade gold exploration prospect in the NWT.

Boss Project, Nevada: a past-producing gold mine in Nevada. A 2013 43-101 Technical Report identified an 8 km by 6 km area that hosts copper gold mineralization and evidence of a copper-gold porphyry system (3).

Macrex Project, BC: a 5,115 acres copper, gold, and silver project located in the Alberni Mining District of British Columbia, approximately 20 km from Port Alberni.

National Instrument 43-101 Technical Report: Updated Mineral Resource Estimate for the Empire Mine Project Custer County, Idaho USA, prepared by Hard Rock Consulting LLC., authors: Jeff Choquette, P.E., State of Montana, J. J. Brown, P.G., SME-RM, and Richard A. Schwering, P.G., SME-RM. Report dated November 25, 2020.GEOLOGICAL ASSESSMENT and EXPLORATION PROPOSAL (2013/14) for the BUENA VISTA PROJECT Copper Kettle Mining District Lovelock Area, prepared by Phil Van Angeren P.Geol. Report dated April 25, 2013.Geological Assessment and Exploration Proposal (2013/2014) for the Boss Project, Goodsprings Mining District” dated September 26, 2013 was prepared by Mr. P Van Angren, P.Geol. Report dated September 26, 2013.
ASSETS OF MTB
Telegraph: 350 square kilometer consolidated land package in the vicinity of 4 notable porphyry deposits being advanced by major mining companies: Galore (Teck/Newmont), Schaft (Teck), Saddle (Newmont) and the operating Red Chris copper-gold mine (Newmont). The property hosts multiple district-scale porphyry copper-gold targets with compelling evidence of fertile copper-gold porphyry systems. Early drilling successes on the Dok trend have outlined a copper-gold bearing porphyry system over 3.3 km and the zone remains open in all directions. MTB has an option with ExGen to earn a 60% interest in the DOK claims, an option to earn a 100% interest in the Dok-X/Yeti claims and a 100% interest in 191 square kilometers of staked claims.

Southmore: 50 square kilometers, 100% owned. The property hosts structurally controlled precious and base metal mineralization; bedded massive sulphides of copper/lead/zinc and skarn mineralization with copper peripheral to intrusions and evidence of underlying porphyry mineralization. Surface samples include a sample with 12.7% copper and another with 29.4 g/t gold.

Royalties: MTB has royalties on 4 projects in the Golden Triangle, encompassing gold, silver and copper, including two past-producing mines.

MTB also holds 480,072 shares of Dolly Varden Silver Corp (DV-NYSE), presently valued at over $3.2 million.

FURTHER DETAILS AND NEXT STEPS

MTB will now seek an interim court order regarding the arrangement and will then hold a special meeting of MTB shareholders, following which MTB will seek a final court order to approve the plan of arrangement. It is anticipated that the special meeting of MTB shareholders will be held in early to mid December.

QUALIFIED PERSONS
Mr. Andrew Wilkins, PGeo. is the Responsible Officer for Lithos Geological Inc. and is the Qualified Person (QP) as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release in so far as it relates to MTB. Mr. Wilkins is a geological consultant with Lithos Geological Inc. He has been QP for MTB and managing MTB’s exploration programs since 2018. Lithos Geological Inc. has a permit to practice #1004267 with the Association of Professional Engineers and Geoscientists of British Columbia.

Kieran Downes, Ph.D., P. Geo., a Qualified Person as defined by National Instrument 43-101, and a director of ExGen, has reviewed and verified the technical information provided in this release, in so far as they relate to ExGen.

OTHER INFORMATION
Completion of the Proposed Transaction is subject to a number of conditions and contingencies being satisfied, waived or removed by one or both of ExGen and MTB, including the approval of MTB's shareholders together with any requisite disinterested shareholder approvals, court approval and acceptance of the TSXV. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the MTB management information circular to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of MTB and ExGen should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release.

ABOUT MTB METALS CORP.
MTB is advancing two copper-gold projects in the prolific Golden Triangle of northern British Columbia. Telegraph: 350 square kilometre property located in the vicinity of 4 notable porphyry deposits all being explored or mined by major mining companies. Field work by MTB, together with earlier results, provides compelling evidence for the presence of one or more porphyries similar to the others in the area. Southmore: 50 square kilometer property hosts several significant copper and gold occurrences. Surface samples include a sample with 12.7% copper and another with 29.4 g/t gold. MTB also holds royalties on four projects in the Golden Triangle, including two past producing mines and it holds 480,072 shares of Dolly Varden Silver.

On behalf of the Board of Directors of MTB:
Lawrence Roulston
President & CEO
For further information on MTB:
Caroline Klukowski, Investor Relations
[email protected]

ABOUT EXGEN RESOURCES INC.
ExGen is a project accelerator that seeks to fund exploration and development of our projects through joint ventures and partnership agreements. This approach significantly reduces the technical and financial risks for ExGen, while maintaining the upside exposure to new discoveries and potential cash flow. ExGen intends to build a diverse portfolio of projects across exploration stages and various commodity groups. ExGen currently has 7 projects in Canada and the US.

On behalf of the Board of Directors of ExGen:
Jason Riley
President & CEO
Tel: 604-688-2641
For further information on ExGen:
Jason Tong
Chief Financial Officer
Email: [email protected]
Cell: 604-889-7827

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains certain forward-looking information. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. In particular, this news release contains forward-looking information in relation to: the Proposed Transaction and the potential completion of the Proposed Transaction, the potential business upon the completion of the Proposed Transaction being a copper, gold and lithium exploration and development company, the potential benefits of the Proposed Transaction to ExGen and MTB shareholders, including the potential creation of a well funded exploration and development company, the potential conditions and satisfaction of those conditions for the completion of the Proposed Transaction, and the potential benefits of the Proposed Transaction to ExGen and MTB shareholders, the potential for near term cash flow from the Empire project, the potential funding of the resulting issuer’s high-risk exploration expenditures by others, the potential expansion of the resulting issuer’s project portfolio of royalties and carried interests, the potential identification of high potential projects, the potential of the DOK property, the potential development of the Golden Triangle, the stronger combined management and technical team, the belief that the metal and resources markets are due for a rebound and that the metals markets are rising, the potential of the resulting issuer to create a near-term production asset and a new porphyry discovery, the potential of the resulting issuer’s combined projects and the provision by ExGen of further updates on a number of potential catalysts across ExGen’s portfolio throughout the rest of this year. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. In the forward looking information contained in this news release, ExGen and MTB have made numerous assumptions, based upon practices and methodologies which are consistent with the mineral industry. In addition, ExGen and MTB have assumed: the satisfaction of any conditions to the Proposed Transaction set in the Arrangement Agreement, including, without limitation, the acceptance of the Proposed Transaction by the TSX-V and typical closing conditions; the receipt of all required approvals for the Proposed Transaction, including TSX-V acceptance, court and any board approvals or third party consents; and market acceptance of the Proposed Transaction. While ExGen and MTB consider these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause ExGen's and MTB’s observations, actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; volatility of commodity prices; competition; accidents and other risks inherent in the mining industry; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including environmental legislation, affecting ExGen or MTB; the early stage development of ExGen and MTB and their projects; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; the possibility that the analytical results from future core sampling does not return significant grades of mineralization; uncertainties relating to interpretation of drill results and the geology; continuity and grade of mineralization; there is no certainty that any work programs will result in significant or successful exploration of ExGen’s and MTB’s projects or development of such projects into a producing mine; uncertainty as to the actual results of exploration and development or operational activities; uncertainty as to the availability and terms of future financing; uncertainty as to timely availability of permits and other governmental approvals; ExGen and MTB may not be able to comply with their ongoing obligations regarding their properties and projects; lack of insurance; currency fluctuations; changes in project parameters as plans continue to be refined; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in ExGen's and MTB’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although ExGen and MTB have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. ExGen and MTB do not undertake to update any forward-looking information except in accordance with applicable securities laws.

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial

October 17, 2025 07:30 ET

 | Source:

Regeneron Pharmaceuticals, Inc.

TARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The European Commission is expected to make a final decision on the application in the coming months. Libtayo was approved by the U.S. Food and Drug Administration (FDA) for these patients in the U.S. earlier this month.

The positive opinion is supported by results from the global Phase 3 C-POST trial investigating adjuvant Libtayo versus placebo in patients with CSCC at high risk of recurrence following surgery and radiation. In the trial, Libtayo reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio [HR]: 0.32; 95% confidence interval [CI]: 0.20-0.51; p<0.0001). Fewer patients treated with Libtayo had locoregional or distant recurrence compared with those who received placebo (4% vs. 17% and 5% vs. 13%, respectively). Detailed data were published in the New England Journal of Medicine (NEJM) in May 2025.

The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers. In the trial, adverse events (AEs) occurred in 91% of patients receiving Libtayo (n=205) and 89% of patients receiving placebo (n=204). Grade ≥3 AEs occurred in 24% and 14% of patients in the Libtayo arm and the placebo arm, respectively. The most common AEs occurring in at least 10% of patients who received Libtayo were fatigue, pruritus, rash, diarrhea, arthralgia, hypothyroidism and maculo-papular rash. The only grade ≥3 AE that occurred in more than 2% of patients in the Libtayo arm was hypertension. AEs led to permanent discontinuation of treatment in 10% of patients who received Libtayo and 2% of patients who received placebo. Two patients in each arm experienced an AE leading to death.

About the Phase 3 Trial
C-POST was a randomized, placebo-controlled, double-blind, multicenter, global Phase 3 trial investigating Libtayo versus placebo as adjuvant treatment for patients with features associated with a high risk of CSCC recurrence and who had completed surgery and post-operative radiation therapy. Trial participants were at high risk of recurrence due to nodal features (extracapsular extension or ≥3 involved lymph nodes) and/or non-nodal features (in-transit metastases, T4 lesion, perineural invasion, or locally recurrent tumor with ≥1 additional poor prognostic features).

The trial enrolled 415 patients who were randomized to receive either Libtayo (n=209) or placebo (n=206) for up to 48 weeks. For the first 12 weeks, Libtayo 350 mg or placebo was administered intravenously every three weeks, followed by Libtayo 700 mg or placebo administered intravenously every six weeks for 36 weeks.

About CSCC
Cutaneous squamous cell carcinoma (CSCC) is a type of non-melanoma skin cancer (NMSC), and one of the most common cancers in the world. In the EU, the incidence of NMSC overall is expected to increase by 40% by 2040. CSCC can often be treated successfully with surgery, but many patients may have a “high risk” form that is more aggressive, and they face an increased risk of recurrence and disease progression.

About Regeneron in Cancer
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.

Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations.

To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care.

About Libtayo  
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced non-small cell lung cancer (NSCLC) and advanced cervical cancer.

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab.   

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

U.S. FDA-approved Indications   
Libtayo is a prescription medicine used to treat:  

Adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC): that has spread or cannot be cured by surgery or radiation, orto help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation. Adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.  Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.
It is not known if Libtayo is safe and effective in children.   

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS  

What is the most important information I should know about LIBTAYO?
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems: cough, shortness of breath, or chest painIntestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tendernessLiver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normalHormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulnessKidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetiteSkin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodesProblems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruisingInfusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swellingRejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have hadComplications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complication Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupushave received an organ or tissue transplant, including corneal transplanthave received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)have received radiation treatment to your chest areahave a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndromeare pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby Females who are able to become pregnant:

Your healthcare provider will give you a pregnancy test before you start treatmentYou should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this timeTell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia).

The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching.

The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite.

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296.

Please see full Prescribing Information, including Medication Guide.  

About Regeneron's VelocImmune Technology  
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo, Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.  

About Regeneron 
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Libtayo® (cemiplimab); the impact of the opinion adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use discussed in this press release on the potential approval by the European Commission of Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (“CSCC”) at high risk of recurrence after surgery and radiation; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Libtayo for the treatment of CSCC in the European Union as discussed in this press release, Libtayo as a monotherapy or in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers, and Regeneron’s other oncology assets in clinical development referenced in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended June 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir ImranAt the closing of the financing, each of Samsara and Anomaly will have the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors, with participation by Mir Imran, the Company’s executive chairman, to purchase shares of its Class A common stock (or pre-funded warrants in lieu thereof), and accompanying warrants to purchase Class A common stock (or pre-funded warrants in lieu thereof) (the “Warrants”) that is expected to result in gross proceeds of approximately $60.3 million, before deducting placement agent fees and other offering expenses. The private placement is expected to close on or about October 21, 2025, subject to the satisfaction of customary closing conditions. The private placement of the shares of Class A common stock (or pre-funded warrants in lieu thereof) was priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC. The accompanying Warrants will only be exercised upon receipt of stockholder approval.

H.C. Wainwright & Co. is acting as the lead placement agent for the private placement. Maxim Group LLC is acting as co-placement agent for the private placement.

The net proceeds from the oversubscribed private placement (but excluding any proceeds from the exercise of the Warrants), together with an initial upfront payment of $10.0 million and the expected technology transfer milestone of $18.0 million from the Collaboration and License Agreement with Chugai Pharmaceuticals Co. Ltd., which was separately announced today, are expected to fund the Company’s operations into 2028. The Company intends to use the net proceeds from the private placement to support the continued advancement of the Company’s pipeline using the RaniPill® platform.

“We are pleased to have priced this additional financing from leading biotech investors, which we believe reflects growing confidence in our strategy. Upon completion, this transaction would meaningfully strengthen our balance sheet and extend our cash runway into 2028, positioning us to advance our RaniPill® platform with clarity, focus, and momentum,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “Together, this financing and our strategic partnership with Chugai Pharmaceuticals Co. Ltd. mark a pivotal moment for Rani. By combining our innovative oral delivery technology with Chugai’s world-class expertise in antibody development and commercialization, we are uniquely positioned to develop a transformative oral therapy that could redefine the treatment landscape for rare diseases globally.”

Private Placement

Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Rani Therapeutics will issue to the investors an aggregate of 42,633,337 shares of Class A common stock at a purchase price of $0.48 per share and pre-funded warrants to purchase up to 82,366,667 shares of Class A common stock at a purchase price $0.4799 per pre-funded warrant. The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable. Each share of Class A common stock and each pre-funded warrant is accompanied by a Class A common stock purchase warrant to purchase one share of common stock (or pre-funded warrant in lieu thereof). The accompanying Warrants to purchase up to 125,000,004 shares of Class A common stock (or pre-funded warrants in lieu thereof) will have an exercise price of $0.48 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants. The Warrants will expire five years following the initial exercise date.

The private placement was led by a new investor Samsara and included a combination of other new and existing stakeholders, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Imran, the Company’s executive chairman. Mr. Imran purchased the securities at a combined purchase price of $0.605 per share and accompanying Warrant, which reflects the consolidated closing bid price of our Class A common stock on October 16, 2025, plus $0.125 per Warrant. The exercise price of the Warrants purchased by Mr. Imran is $0.48 per share, which reflects the consolidated closing bid price of the Class A common stock on October 16, 2025.

At the closing of the financing, each of Samsara and Anomaly will have the right to designate one member of the Company’s board of directors.

Debt Conversion

In connection with the private placement, Avenue Venture Opportunities Fund will convert $6 million of outstanding debt into 12,500,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and will receive Warrants to purchase up to 12,500,000 shares of Class A common stock (or pre-funded warrants in lieu thereof), and otherwise on the same terms as the other investors in the private placement, reducing the Company’s total debt obligations.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, or any state or other applicable jurisdictions’ securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with the execution of the securities purchase agreement, Rani Therapeutics and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of Class A common stock and the Class A common stock issuable upon exercise of the pre-funded warrants and the Warrants, sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected gross proceeds and closing date of the private placement financing, our belief that the successful capital raise reflects growing confidence and strong endorsement in our strategy, our expectation to be able to fund the Company’s operations into 2028, the intended use of the net proceeds from the private placement financing, ability to obtain stockholder approval for the warrants, our ability to receive of milestone payments under the Collaboration and License Agreement with Chugai Pharmaceuticals and the success of our collaboration with Chugai, our ability to repay the remaining principle of the debt obligation with Avenue, and our ability to develop a transformative oral therapy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “potential,” “expect,” “may,” “could” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:
[email protected] 

Media Contact:
[email protected] 

Robesonia, PA, October 17, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure company, today announced the integration of a powerful open-source DeFi on‑ramp and off‑ramp protocol across its entire ecosystem — including consumer-facing platforms ShopWithCrypto.io, ZEUSxPay.io, and the Apollo Wallet. This integration enables seamless conversion between fiat and crypto using widely adopted payment systems such as Cashapp, PayPal, Venmo, Zelle, Wise, and Revolut.

Seamless Onboarding and Offboarding via Familiar Payment Rails

Through this new embedded infrastructure:

ShopWithCrypto.io now supports on‑ramp, allowing non-crypto native users to purchase digital assets using familiar payment apps.
ZEUSxPay.io enables off‑ramp, so merchants can instantly convert crypto revenue into fiat and withdraw to preferred platforms.
Apollo Wallet, Blaqclouds’ flagship Web3 wallet, now provides built-in on‑ramp and off‑ramp functionality, allowing users to move fluidly between fiat and digital assets without ever leaving the wallet interface.

DeFi-Powered, Open Architecture

This DeFi-Powered technology is managed by layers of smart contracts with real-time token bridging and swapping  running on a private API architecture. The system is designed to enable:

Fiat on-ramps via Cashapp. PayPal, Venmo, Zelle, Wise, and Revolut
Crypto-to-fiat off‑ramps with near-instant settlement
Smart routing for currency exchange optimization
Built-in fraud monitoring, compliance rails, and secure APIs
Global currency support for diverse user and merchant bases

By embedding this infrastructure natively into Apollo Wallet and Blaqclouds applications, the company eliminates friction points associated with external exchanges and custodians.

Driving Real-World Utility

This strategic integration extends the Blaqclouds mission of driving real-world usability and mainstream adoption of crypto. It opens the door for:

Frictionless entry for Web2 users and crypto novices
Revenue conversion for merchants accepting supported tokens on ZEUSxPay.io
A single wallet hub that supports full DeFi lifecycle: acquire → transact → off-ramp

“This revolutionary DeFi integration is a pivotal leap forward in our ecosystems development. We’ve eliminated the barriers between fiat and crypto without the need for centralized interference or managed 3rd parties. Whether you’re a first-time buyer on ShopWithCrypto, a business owner using ZEUSxPay, or a power user on Apollo Wallet, the transition between Web2 money and Web3 assets is now seamless, secure, and embedded. This is the evolution of digital finance in real life.”

Shannon Hill, CEO of Blaqclouds
About Blaqclouds, Inc.
Blaqclouds bridges traditional finance and decentralized ecosystems, building seamless, real-world blockchain applications that simplify commerce and payments. Its mission is to make spending crypto as easy, trusted, and usable as traditional currency.

Flagship consumer applications include:
– ShopWithCrypto.io – Crypto-to-gift card commerce
– ZEUSxPay.io – Web3 payments and merchant plugins
– DEX.ZEUSx.io – EVM-compatible decentralized exchange
– ApolloWallet.io – Secure, consumer-grade blockchain wallet

For a full list of platforms and solutions from Blaqclouds Nevada and Wyoming, visit: www.blaqclouds.io.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Blaqclouds, Inc. to accomplish its stated plan of business. Blaqclouds, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Blaqclouds Inc. or any other person. This press release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve certain risks and uncertainties that may cause actual results to differ materially. Blaqclouds, Inc. assumes no obligation to update or revise any forward-looking statements.

Media Contact
Blaqclouds, Inc.
c/o www.theAlley.io
Email: [email protected]
Phone: 307-323-4430
Website: www.blaqclouds.io

Source: Blaqclouds, Inc.

Here's why we believe Iridium Communications (IRDM) stock deserves your attention: It is growing, generating cash, and is available at a substantial valuation discount. Let’s review the numbers.

Cash Yield: Iridium Communications boasts an impressive cash flow yield of 16.2%.Growing: The revenue growth over the last 12 months is 7.6%, indicating that the cash reserves are expected to increase.Valuation Discount: Currently, IRDM stock is trading 46% below its 3-month high, 47% below its 1-year high, and 59% below its 2-year high.Free Cash Flow Yield is defined as free cash flow per share divided by stock price. Why is it important? If a company generates a high amount of cash per share, it can be utilized for further revenue growth or distributed to shareholders through dividends or buybacks. For a brief background, Iridium Communications delivers mobile voice, data, push-to-talk, broadband, and IoT communication services to businesses, governments, NGOs, and consumers via a wholesale distribution network.

Investing in a single stock can be risky; however, there is significant value in the more diversified strategy we adopt with the Trefis High-Quality Portfolio. Furthermore, consider how your portfolio's long-term performance could improve by allocating 10% to commodities, 10% to gold, and 2% to crypto alongside equities.

Comparison with S&P500 Median

Trefis

But do these statistics provide a complete perspective? Read Buy or Sell IRDM Stock to determine if Iridium Communications still possesses a competitive advantage that remains sustainable.

The Message? The Market Can Recognize and RewardThe following statistics are derived from the “high FCF yield with growth and discount” selection strategy since 12/31/2016. The statistics are calculated based on monthly selections, with the assumption that once a stock is selected, it cannot be re-selected for the subsequent 180 days.

Average forward returns over 6 months and 12 months of 25.7% and 57.9% respectivelyWin rate (percentage of picks that return positive) of over 70% for both 6-month and 12-month durationsHowever, Be Aware of the RisksThat being said, IRDM is not shielded from significant declines. It experienced a drop of approximately 31% during the Global Financial Crisis and nearly a 30% decrease during the 2018 correction. The COVID pandemic had an even greater impact, resulting in a 44% decline, followed by an inflation shock that caused it to drop nearly 47%. Even with solid fundamentals, considerable pullbacks occur when the markets become turbulent.

However, the risks are not confined to large market crashes. Stocks can decline even when the markets are performing well – consider events such as earnings reports, business updates, and changes in outlook. Read IRDM Dip Buyer Analyses to see how the stock has rebounded from sharp declines in the past.

Consistently selecting winners is a challenging endeavor – especially with the potential volatility associated with a single stock. Alternatively, the Trefis High Quality (HQ) Portfolio, which consists of 30 stocks, has demonstrated a track record of significantly outperforming the S&P 500 over the past 4 years. Why is this the case? Collectively, HQ Portfolio stocks have provided superior returns with lower risk compared to the benchmark index; offering a smoother ride, as illustrated by HQ Portfolio performance metrics.

Investors seeking momentum may have Aberdeen Standard Physical Palladium Shares ETF (PALL - Free Report)  on radar now. The fund recently hit a new 52-week high. Shares of PALL are up approximately 80.2% from their 52-week low of $82.39/share.

But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.

PALL in FocusPALL reflects the performance of the price of palladium, less Trust's expenses. The shares are designed for investors who want a cost-effective and convenient way to invest in physical palladium. PALL charges 60 basis points in fee per year and has AUM of $907.8 million (see all Precious Metals ETFs here).

Why the move?Rising tensions in the U.S.-China trade relations, have been giving a boost to the palladium prices. Many have probably been considering the metal as a safe-haven asset.Expectations of US interest rate cuts and the potential decline in the price of the greenback have also been favoring the metal.

More Gains Ahead?PALL has a Zacks ETF Rank #3 (Hold) with a High risk outlook. However, the fund has a weighted alpha of 74.94. So, the fund can surge a bit higher if the operating environment remains favorable.

, /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, today announced that it has signed a Memorandum of Understanding (MOU) with ChainUp, a blockchain technology and digital asset exchange solutions provider, to co-develop a global blockchain infrastructure platform to support institutional-grade crypto investment products and related financial services.

The partnership marks a significant step in Yiren Digital's long-term growth strategy to develop a transparent, efficient, and compliant next-generation fintech platform. It also aligns with the Company's focus on long-term value creation by capturing opportunities at the accelerating convergence of traditional finance and emerging Web3 technologies.

Yiren Digital began building up its Web3 assets in the first quarter of 2025 by investing directly in Ethereum (ETH), laying the groundwork for future blockchain-based product development. In June 2025, the Company established a digital asset task force in Hong Kong to explore regulated opportunities within the city's fast-developing digital finance ecosystem.

"Our entry into blockchain finance represents a long-term growth catalyst for Yiren Digital," said Mr. Ning Tang, Chairman and CEO of Yiren Digital. "This partnership accelerates the development of our Web3 ecosystem, supporting our ability to build the next-generation fintech platform based on digital asset and innovative asset tokenization technology that combine the immutability and security of blockchain with the solid strength of our fintech foundation. We see this as a unique and strategic opportunity to redefine how investors and asset owners engage with digital finance globally."

Yiren Digital plans to launch an initial functional release of the new crypto finance system by the end of October 2025. This early release will be accessible to selected users to experience the staking of their Ethereum and provide valuable performance and compliance feedback. Building on this foundation, the Company expects to deliver the full version 1.0 in the first half of 2026, introducing complete product features, expanded asset coverage, and integrated connectivity with its existing fintech ecosystem.

Yiren Digital's long-term vision includes establishing a comprehensive blockchain-enabled financial ecosystem that offers diversified digital asset investment and tokenization services for both investors and asset owners. The platform bridges traditional fintech with blockchain infrastructure, enabling asset owners to unlock liquidity through tokenization of real-world assets (RWA). This creates new opportunities for investors to diversify their portfolio by accessing previously hard-to-reach asset classes.

According to Global Industry Analyst Inc. (October 2025), the global digital asset market is undergoing rapid institutionalization. Its market capitalization now exceeds USD4.2 trillion, with blockchain-based financial services projected to surpass USD52.2 billion by 2030, growing at a compound annual growth rate of more than 45%.

Yiren Digital believes its early and strategic entry positions it to capture meaningful market share as digital assets evolve from speculative instruments into a mainstream component of global financial infrastructure.

Headquartered in Singapore, ChainUp is a leading blockchain solutions provider offering digital asset exchange systems, custody, Web3 infrastructure, and asset tokenization services. The company serves more than 1,000 clients across over 30 markets, reaching more than 60 million end users, and was named Regulation Asia's "Best Institutional Custody & Asset-Servicing Solution" in 2023.

About Yiren Digital
Yiren Digital Ltd. is a leading fintech company specializing in digital consumer lending, insurance, and financial technology innovation across China and Southeast Asia. The Company leverages advanced artificial intelligence and emerging technologies to enhance customer experience, optimize capital efficiency, and expand financial inclusion. With the recent launch of its Magicube Agent Platform and its strategic entry into crypto and blockchain finance, Yiren Digital is building a new growth engine to become an AI-powered and blockchain-enabled global fintech leader. For more information, please visit https://ir.yiren.com.

Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Yiren Digital's control. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in any such statements. Further information regarding these and other risks, uncertainties or factors is included in Yiren Digital's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Yiren Digital does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

SOURCE Yiren Digital

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

ATLANTA--(BUSINESS WIRE)--Carter's, Inc. (NYSE: CRI), North America's largest and most-enduring apparel company exclusively for babies and young children, will report its third quarter fiscal 2025 results before the market opens on Monday, October 27, 2025. The Company will host a conference call to discuss its results and provide an update on its business on this date at 8:30 a.m. Eastern Daylight Time. To listen to a live webcast and view the accompanying presentation materials, please visit.

Pearson plc (NYSE:PSO) Q3 2025 Sales Call October 17, 2025 3:30 AM EDT

Company Participants

Omar Abbosh - CEO & Executive Director
Sally Kate Johnson - CFO & Executive Director

Conference Call Participants

James Tate - Goldman Sachs Group, Inc., Research Division
Adam Berlin - UBS Investment Bank, Research Division
Nick Dempsey - Barclays Bank PLC, Research Division
Steven Craig Liechti - Deutsche Bank AG, Research Division

Presentation

Unknown Executive

Good morning, everyone, and welcome to Pearson's 2025 9-month Trading Update. [Operator Instructions]. And with that, I'll hand over to Omar.

Omar Abbosh
CEO & Executive Director

Good morning, everyone, and thank you for joining us today for our 2025 9-month trading update. I'm here in London with our CFO, Sally Johnson. And as always, I appreciate your time and interest in Pearson's journey as we continue to renew this company by executing against the 3 key priorities that we set out at the start of the year. You'll have seen this morning's announcement already. So I'll just pick out a few points on our progress, and then we'll open it up for Q&A.

Firstly, on our financial performance. Sales growth accelerated to 4% in Q3, and I'm pleased with the broad-based execution across our teams that they're showing and in particular, the way that we're navigating the market headwinds that I outlined at our interim results. When we look at the business units, Virtual Learning delivered a really standout result in the back-to-school period with 17% sales growth, driven by excellent enrollment performance, reflecting improvements in our digital marketing approach, enrollment process and career offering.

Assessment & Qualifications growth accelerated to 4% in Q3, with Pearson VUE returning to growth as expected, driven by new contract launches. These were offset in part by ongoing headwinds in federal hiring and spending that continues to affect PDRI. In Enterprise Learning & Skills, we

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

A staff member cleans a Xiaomi SU7 electric vehicle displayed at the Beijing International Automotive Exhibition, or Auto China 2024, in Beijing, China, April 25, 2024. REUTERS/Tingshu Wang/File Photo Purchase Licensing Rights, opens new tab

CompaniesBEIJING, Oct 17 (Reuters) - Shares of Chinese EV maker Xiaomi

(1810.HK), opens new tab suffered their biggest weekly loss in more than 3-1/2 years on Friday, after media reported two separate accidents involving its best-selling model this week.

Xiaomi shares ended the day 3.7% lower at HK$45.96 ($5.92), the lowest close since April 22. For the week, they tumbled 11.7%, the worst such decline since late January 2022, though year-to-date, the shares are still up by a third.

Sign up here.

On Friday morning a SU7 sedan lost control in the central city of Wuhan, where it knocked down guard rails in the middle of the road, drove into the opposite lane and collided with a van, according to the Sanxiang Metropolitan Daily, a government-backed newspaper.

Video from the scene circulated by the newspaper showed the car's left front wheel axle had broken. It was not clear if there were any casualties.

That followed an incident on Monday involving a 31-year-old man, suspected of drunk driving, who was killed in a collision in Chengdu. When passersby tried to pull him out of his burning SU7 Ultra they were unable to open the car doors, Chinese media reported.

Xiaomi hasn't publicly acknowledged that the accidents involved its electric vehicles. Chinese police issued a statement that detailed the Chengdu incident but did not name Xiaomi.

The company didn't respond to a request for comment.

In a speech to an industry event in Beijing on Thursday, his first public appearance after the Chengdu accident, Xiaomi CEO Lei Jun made no mention of the crash, but called on the industry to focus resources and energy on technology R&D under the government's guidance and with safety as the basis.

He also urged a joint boycott of online trolls and malicious negative campaigns.

The Chinese smartphone maker turned EV maker launched the SU7 in March 2024. The electric sedan had begun outselling Tesla's

(TSLA.O), opens new tab Model 3 on a monthly basis since December, before handing the lead back in September.

Under a product recall issued last month by the market regulator, Xiaomi announced a software update for over 115,000 SU7 sedans to fix potential safety issues when its assisted driving features are used.

It saw bumper orders for its electric SUV YU7 in late June, despite a deadly crash involving an SU7 in assisted driving mode at the end of March.

($1 = 7.7668 Hong Kong dollars)

Reporting by Beijing, Shanghai and Hong Kong newsrooms; Editing by David Dolan and Kim Coghill

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Photo by FABRICE COFFRINI/AFP via Getty Images

AFP via Getty Images

META is Alphabet's counterpart within the Interactive Media & Services sector that possesses:

1) A lower valuation (P/OpInc) in comparison to Alphabet stock
2) Yet higher revenue and operating income growth

This disparity between valuation and performance could suggest that investing in META stock is more advantageous than purchasing GOOGL stock

Investing in individual stocks can be precarious, but there is significant value in adopting a broader diversified strategy as we do with Trefis High Quality Portfolio. Trefis collaborates with Empirical Asset Management – a wealth management firm in the Boston area – which has implemented asset allocation strategies yielding positive returns during the 2008-09 timeframe when the S&P declined over 40%. Empirical has integrated the Trefis HQ Portfolio into this asset allocation strategy to deliver improved returns with reduced risk compared to the benchmark index; providing a smoother investment experience, as shown in the HQ Portfolio performance metrics.

Key Metrics AssessmentsKey Metrics Assessments

Trefis

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

Do these figures, however, encompass the entire picture? Read Buy or Sell GOOGL Stock to determine if Alphabet still possesses an advantage that remains viable beneath the surface. For context, Alphabet (GOOGL) offers a variety of products and services, including advertising, Android, Chrome, hardware, cloud solutions, health technology, and internet services across diverse markets.

This is merely one method for assessing investments. The Trefis High Quality Portfolio conducts a more comprehensive evaluation and is designed to mitigate stock-specific risks while providing potential growth opportunities.

Is The Discrepancy In Stock Prices Temporary?A method to evaluate whether Alphabet stock is currently overpriced compared to other tickers would involve examining how these metrics compared among companies exactly one year ago. Specifically, if there has been a notable trend reversal for Alphabet over the past 12 months, then the ongoing disparity may likely reverse. Conversely, sustained underperformance in revenue and operating income growth for Alphabet would reinforce the notion that its stock is overpriced relative to its competitors but might not revert soon.

Key Metrics Compared 1 Year AgoKey Metrics Compared 1 Year Ago

Trefis

OpInc = Operating Income

Other Metrics To Think AboutOther Metrics To Think About

Trefis

Considering buying based on valuation, while appealing, must be assessed thoroughly from various perspectives. This multi-faceted evaluation is precisely how we develop Trefis portfolio strategies. If you desire potential gains with a more stable journey than an individual stock offers, explore the High Quality portfolio, which has surpassed the S&P, delivering over 91% returns since its inception.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of EPD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HAMILTON, Bermuda--(BUSINESS WIRE)--Essent Group Ltd. (NYSE: ESNT) today announced that it will hold a conference call on Friday, November 7, 2025, at 10:00 a.m. Eastern Time to discuss the Company’s third quarter 2025 results, which will be announced prior to the market open on the same day.

The conference call will be broadcast live over the Internet at http://ir.essentgroup.com/events-and-presentations/events/default.aspx. The call may also be accessed by dialing 888-330-2384 inside the U.S., or 240-789-2701 for international callers, using passcode 9824537 or by referencing Essent.

A replay of the webcast will be available on the Essent website approximately two hours after the live broadcast ends for a period of one year. A replay of the conference call will be available approximately two hours after the call ends for a period of two weeks, using the following dial-in numbers and passcode: 800-770-2030 inside the U.S., or 647-362-9199 for international callers, passcode 9824537.

In addition to the information provided in the Company's earnings news release, other statistical and financial information, which may be referred to during the conference call, will be available on Essent's website at http://ir.essentgroup.com/financials/quarterly-results/default.aspx.

About the Company

Essent Group Ltd. (NYSE: ESNT) is a Bermuda-based holding company (collectively with its subsidiaries, “Essent”) offering private mortgage insurance, reinsurance, and title insurance and settlement services to serve the housing finance industry. Additional information regarding Essent may be found at www.essentgroup.com.

More News From Essent Group Ltd.

Technical Report Highlights: Base Case shows US$66.2M post tax NPV5, 24.4% IRR, with a payback multiple of 1.9 at a US$2,300/oz gold price Upside Case shows US$243.3M post tax NPV5, 168.4% IRR, with a payback multiple of 8.4 at a US$3,500/oz gold price 286k ounces of gold produced at an AISC of US$1,626 per AuEq ounce over a 6.1-year mine life with US$45M initial CAPEX US$40M increase in base case post-tax NPV5 and US$9.4M reduction in initial capital expenditure from the previous technical report La Colorada Indicated Mineral Resources grow by 62k ounces to 513k ounces, grading 0.79 grams per tonne Expansion potential with Veta Madre Plus. Potential to convert up to 28k Indicated Mineral Resource ounces to Mineral Reserves to support a larger pit with drilling to be completed in Q4, 2025 Permits received in August and September 2025 to expand the leach pad at La Colorada Vancouver, British Columbia--(Newsfile Corp. - October 17, 2025) - Heliostar Metals Ltd.

, /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) reported its third quarter 2025 results today. Investors can access the live third quarter 2025 earnings call at 8 a.m. ET today by webcast or dial-in as follows:

Webcast: app.webinar.net/mdQ0gY4Vl61
Dial-in: 1-877-883-0383, passcode 4433280

The earnings release, investor presentation, including an appendix reconciling non-GAAP disclosures, and Truist's Third Quarter 2025 Quarterly Performance Summary, which contains detailed financial schedules, are available at Truist's Investor Relations website at https://ir.truist.com/earnings. A replay of the call will be available on the website for 30 days.

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $544 billion as of September 30, 2025. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Chinese robotaxi company Pony.ai announced Friday it is working with Stellantis for testing self-driving taxis in Europe.

The companies said they will start tests in the coming months in Luxembourg, where Pony.ai's European division is headquartered. Starting next year, the companies plan "a gradual rollout across European cities."

Pony.ai will provide the autonomous driving software, while Stellantis — which owns brands including Chrysler, Citroën and Jeep — will provide the electric vehicles, starting with the Peugeot e-Traveller.

Deploying robotaxis for the mass market typically starts with local testing on public roads in order to establish a safety track record for obtaining regulatory approval.

"Pony.ai stands out for their technical expertise and collaborative approach,"

Stellantis' Chief Engineering and Technology Officer Ned Curic said that Pony.ai is known for its "technical expertise and collaborative approach." He noted that the automaker has built car systems for autonomous driving integration and is "partnering with the best players in the industry."

Major U.S. and Chinese cities have been some of the first in the world to allow local companies to operate public-facing robotaxis.

The companies have, in the last year, ramped up efforts to expand to the Middle East and Europe.

Earlier this week, U.S. robotaxi operator Waymo announced plans to start tests in London before launching the self-driving taxi service there next year. Waymo is owned by Google parent Alphabet.

Pony.ai and its Chinese rival WeRide are both listed in the U.S. The two companies this week received Chinese regulatory approval for their plans to offer shares in a dual listing in Hong Kong.

—CNBC's Lora Kolodny contributed to this report.

These companies' market-beating fuel hasn't run out yet.

Cathie Wood, the chief executive officer of Ark Invest, can be somewhat of a polarizing figure, with some research indicating that her investment firm's actively managed exchange-traded funds (ETFs) have significantly destroyed shareholder value over the long run. Even if that's the case, let's give credit where credit is due. Some of Wood's picks have been fantastic performers, at least over the course of the current fiscal year. Two of them are CRISPR Therapeutics (CRSP -4.72%) and Spotify Technologies (SPOT -1.26%). What's more, both of these stocks have excellent prospects and could continue delivering above-average returns for a while.

Image source: Getty Images.

1. CRISPR Therapeutics
Shares of CRISPR Therapeutics, a mid-cap biotech focusing on gene editing, are up about 85% this year as the company's most advanced pipeline programs look increasingly promising. Few things can jolt a drugmaker's shares like strong clinical and regulatory progress. That's what could power CRISPR Therapeutics in the next few years. The company's CTX310 seeks to lower LDL cholesterol and triglycerides (TGs), harmful fats that can cause heart disease, stroke, and other cardiovascular conditions. With some 40 million people in the U.S. with elevated levels of either, there is a significant need for new treatment options.

CTX310 is still in the early stages of development. In an ongoing study, the medicine is showing success in lowering LDL and TGs in certain patients.

The company's other promising programs include CTX112, being developed to treat certain types of blood cancers, and CTX320, a therapy that could help lower lipoprotein(a), which, at high levels, can cause heart attacks. CRISPR Therapeutics' gene-editing approach could help raise the standards, leading to better outcomes than currently available therapies. Further, the company already has an approved medicine on the market, called Casgevy, which it developed with Vertex Pharmaceuticals. Casgevy, a medicine for a pair of rare blood disorders, isn't making massive contributions to CRISPR Therapeutics yet, but it could in a few years.

In the meantime, the company could launch -- or at least get close to launching -- one or two brand-new medicines while riding the wave of successful clinical trials. There are risks involved, naturally. Notably, potential clinical setbacks. It's essential to keep that in mind. However, given CRISPR Therapeutics' attractive pipeline for a biotech company of its size, promising results across various programs, and prior success in launching a gene-editing medicine, the company's prospects look promising. The stock could have plenty of upside even after its strong run this year.

2. Spotify Technologies
Spotify Technologies is the leading music streaming platform. That's a significant achievement. Companies like Apple, Amazon, and Alphabet -- three of the largest and most cash-rich corporations in the world -- are in this business and could use their diversified operations to run their music streaming units at a loss to attract customers, thereby undercutting Spotify's efforts.

Despite this risk, Spotify has the top market share worldwide, and the market has started to recognize this -- the shares are up about 50% in 2025. It has built a strong brand name tied to the services it offers and maintained a lead thanks to its deep network effect. The more its ecosystem grows, the more attractive it becomes to artists seeking a broad audience and publicity.

Spotify has also made smart moves, such as its push into podcasting, that have helped the platform grow, albeit at the cost of lower margins in that business. That may not have been ideal for a company that wasn't profitable, but Spotify has made significant progress on the bottom line in recent quarters.

SPOT Net Income (TTM) data by YCharts

The future should remain bright for the music streaming service. Spotify ended the second quarter with 696 million monthly active users (MAUs), up 11% year over year. However, less than half of those, just 276 million, were premium subscribers. Spotify can increase its revenue by turning more of its users into paying ones and by attracting even more business to its platform. The company is pushing to reach 1 billion MAUs by 2030, which is an attainable goal considering its current position and track record.

Lastly, Spotify has improved its platform through artificial intelligence-related initiatives, such as its virtual assistant, Spotify DJ, which is helping drive engagement on the platform, something that could lead to higher ad sales. With all that going on, the company's future looks bright.

Prosper Junior Bakiny has positions in Alphabet, Amazon, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, CRISPR Therapeutics, Spotify Technology, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Coca-Cola Co. is considering taking its Indian bottling arm, Hindustan Coca-Cola Beverages Pvt. (HCCB), public, as per a Bloomberg report.

Palantir's stock has gotten overheated, which has opened the door for other tech businesses to overtake it in size.

Palantir Technologies (PLTR -0.98%) has been one of the most popular artificial intelligence (AI) investments in recent years, and for a good reason: It has delivered incredible returns to its shareholders. If you had invested $10,000 in it as the generative AI race took off at the start of 2023, your investment would have grown to be worth about $280,000 today. That's an unbelievable return in a relatively short time frame, but not all of those gains have been earned yet by the company. With Palantir trading at a price-to-earnings ratio of close to 600, a lot of expected future growth is already priced into the shares. 

Given how overheated it has become, I don't anticipate its current growth spurt lasting much longer. I believe that could set up ASML (ASML 0.79%) and AMD (AMD -1.70%) to pass Palantir's market cap -- currently $426 billion -- by late 2026.

Image source: Getty Images.

Years' worth of aggressive growth assumptions are baked into Palantir's stock price
AMD and ASML's market caps are slightly smaller than Palantir's, at $350 billion and $405 billion, respectively. However, I think they could easily catch up, although their share price gains may not be based solely on their own immediate performance.

Although Palantir's stock is up around 2,700% since the start of 2023, its revenue has only risen by 80%. That's a huge mismatch, and it points to multiple expansion as the reason for Palantir's stock rise. While this mechanism can drive long-term shareholder returns (Apple stock is a great example), it's only reasonable to a certain level.

Palantir seems to have exceeded that level. Beyond its lofty trailing P/E ratio, it trades for 130 times trailing sales and 276 times forward earnings.

PLTR PE Ratio (Forward) data by YCharts.

These are unbelievable premiums that far exceed the valuation levels most stocks ever reach. However, because Palantir's growth rate is still accelerating, its market cap has continued to rise. As soon as Palantir's growth rate slows, I expect the stock to rapidly tumble.

Let's say that Palantir can grow its revenue at a sustained 50% pace over the next six years. Assume also that it can achieve a 35% profit margin. If it does, revenue and profits would grow from $3.44 billion and $772 million today to $39.2 billion and $13.7 billion six years from now. That would be an unprecedented sustained growth rate, but even if it achieves those things, the stock would still be valued at 31 times forward earnings. For reference, Nvidia, the king of AI hardware, trades for 30 times its expected 2026 earnings.

That's far too great a price to pay for Palantir, especially considering how unbelievably bullish the assumptions I've postulated are. I think this situation has left it vulnerable to a correction.

AMD and ASML are critical to the AI arms race
While AMD has long been a second-place player to Nvidia in the race to develop the GPUs that have become essential AI hardware, its fortunes seem to be changing. AMD and ChatGPT developer OpenAI recently announced a partnership under which OpenAI will buy up to 6 gigawatts of computing power from the chipmaker. As part of the deal, OpenAI will also wind up with new shares equal to about 10% of AMD, once all milestones are met.

While there are some questions surrounding how this deal will play out, AMD could see a ripple effect of other customers switching some of their GPU purchases from Nvidia's hardware to AMD's cheaper (but similarly capable) alternatives. This could drive a ton of excitement about AMD's stock, which is already up by about 40% in October. If business gains follow, AMD could easily be a bigger company than Palantir this time next year.

ASML is another key player in the AI realm. Its extreme ultraviolet (EUV) lithography machines are the only ones on Earth capable of manufacturing today's highest-end chips. Without them, AI technology as we know it wouldn't be the same.

ASML's vital role in the chip manufacturing process is secure because it has a technological monopoly on its product line. Such situations are quite rare, and when investors identify them, they should take action and invest accordingly. More of ASML's machines will be required to meet rising chip demand, which should help the company deliver solid growth in 2026. While investors shouldn't expect the stock to rocket higher, I think it can solidly beat the market.

Not only do ASML and AMD have solid growth trends acting in their favor, both are priced at much more reasonable valuations than Palantir is. AMD trades at 55 times forward earnings while ASML trades at 35 times forward earnings. That difference in their premiums will likely be enough to tip the scales in favor of AMD and ASML by the end of next year, which makes them better investments now.

Keithen Drury has positions in ASML and Nvidia. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Apple, Nvidia, and Palantir Technologies. The Motley Fool has a disclosure policy.